Mallinckrodt and Endo, drugmakers which recently emerged from bankruptcy after a wave of U.S. opioid lawsuits, announced ...

Mallinckrodt and Endo are merging in a $6.7 billion deal, with a pro forma NYSE listing and $900 million in financing.

The two companies are merging after previously filing for bankruptcy due to opioid-related litigation and financial losses.

The Mallinckrodt-Endo combination will have approximately 5,700 employees at closing, as well as 17 manufacturing facilities, 30 distribution centers, and an operating footprint primarily located in ...

Dublin-headquartered Mallinckrodt is taking over smaller rival Endo and planning to list the combined firm on the New York ...

Wachtell, Lipton, Rosen & Katz is steering Mallinckrodt Pharmaceuticals and Davis Polk & Wardwell is guiding Endo Inc. in ...

The merger will give the combined entity the financial flexibility to pursue drug licensing deals and broaden its therapeutic ...

Wilmington, Delaware-- (Newsfile Corp. - March 13, 2025) - Rigrodsky Law, P.A. is investigating Endo, Inc. ("Endo") (OTC: NDOI) regarding possible breaches of fiduciary duties and other violations of ...

The pairing of Mallinckrodt plc and Endo Inc. is expected to create a pharma heavyweight that will generate $3.6 billion in 2025 revenue after the duo combines their generic pharmaceuticals businesses ...

Malvern-based Endo has agreed to merge with Mallinckrodt in a cash and stock deal, valuing the combined pharmaceutical company at $6.7 billion, writes ...

Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report.

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed merger of Endo, Inc. (OTC: NDOI) and Mallinckrodt plc.